Chong Lee-Yee, Clarkson Jan E, Dobbyn-Ross Lorna, Bhakta Smriti
UK Cochrane Centre, Oxford, UK.
Cochrane Database Syst Rev. 2018 Mar 1;3(3):CD005101. doi: 10.1002/14651858.CD005101.pub4.
Slow-release fluoride devices have been investigated as a potentially cost-effective method of reducing dental caries in people with high risk of disease. This is the second update of the Cochrane Review first published in 2006 and previously updated in 2014.
To evaluate the effectiveness and safety of different types of slow-release fluoride devices on preventing, arresting, or reversing the progression of carious lesions on all surface types of primary (deciduous) and permanent teeth.
Cochrane Oral Health's Information Specialist searched the following electronic databases: Cochrane Oral Health's Trials Register (to 23 January 2018); the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 12) in the Cochrane Library (searched 23 January 2018); MEDLINE Ovid (1946 to 23 January 2018); and Embase Ovid (1980 to 23 January 2018). The US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform were searched for ongoing trials (23 January 2018). We placed no restrictions on the language or date of publication when searching the electronic databases.
Parallel randomised controlled trials (RCTs) comparing slow-release fluoride devices with an alternative fluoride treatment, placebo, or no intervention in all age groups. The main outcome measures sought were changes in numbers of decayed, missing, and filled teeth or surfaces (DMFT/DMFS in permanent teeth or dmft/dmfs in primary teeth), and progression of carious lesions through enamel and into dentine.
We conducted data collection and analysis using standard Cochrane review methods. At least two review authors independently performed all the key steps in the review such as screening of abstracts, application of inclusion criteria, data extraction, and risk of bias assessment. We resolved discrepancies through discussions or arbitration by a third or fourth review author.
We found no evidence comparing slow-release fluoride devices against other types of fluoride therapy.We found only one double-blind RCT involving 174 children comparing a slow-release fluoride device (glass beads with fluoride were attached to buccal surfaces of right maxillary first permanent molar teeth) against control (glass beads without fluoride were attached to buccal surfaces of right maxillary first permanent molar teeth). This study was assessed to be at high risk of bias. The study recruited children from seven schools in an area of deprivation that had low levels of fluoride in the water. The mean age at the beginning of the study was 8.8 years and at the termination was 10.9 years. DMFT in permanent teeth or dmft in primary teeth was greater than one at the start of the study and greater than one million colony-forming units of Streptococcus mutans per millilitre of saliva.Although 132 children were still included in the trial at the two-year completion point, examination and statistical analysis was performed on only the 63 children (31 in intervention group, 32 in control group) who had retained the beads (retention rate was 47.7% at 2 years). Among these 63 children, caries increment was reported to be statistically significantly lower in the intervention group than in the control group (DMFT: mean difference -0.72, 95% confidence interval (CI) -1.23 to -0.21; DMFS: mean difference -1.52, 95% CI -2.68 to -0.36 (very low-quality evidence)). Although this difference was clinically significant, it only holds true for those children who maintain the fluoride beads; over 50% of children did not retain the beads.Harms were not reported within the trial report. Evidence for other outcomes sought in this review (progression to of caries lesion, dental pain, healthcare utilisation data) were also not reported.
AUTHORS' CONCLUSIONS: There is insufficient evidence to determine the caries-inhibiting effect of slow-release fluoride glass beads. The body of evidence available is of very low quality and there is a potential overestimation of benefit to the average child. The applicability of the findings to the wider population is unclear; the study had included children from a deprived area that had low levels of fluoride in drinking water, and were considered at high risk of caries. In addition, the evidence was only obtained from children who still had the bead attached at 2 years (48% of all available children); children who had lost their slow-release fluoride devices earlier might not have benefited as much from the devices.
缓释氟化物装置已被作为一种潜在的具有成本效益的方法进行研究,用于降低疾病高风险人群的龋齿发生率。这是Cochrane系统评价的第二次更新,该评价首次发表于2006年,此前于2014年进行过更新。
评估不同类型的缓释氟化物装置在预防、阻止或逆转乳牙和恒牙所有表面类型龋损进展方面的有效性和安全性。
Cochrane口腔健康信息专家检索了以下电子数据库:Cochrane口腔健康试验注册库(截至2018年1月23日);Cochrane图书馆中的Cochrane对照试验中央注册库(CENTRAL;2017年第12期,检索于2018年1月23日);MEDLINE Ovid(1946年至2018年1月23日);以及Embase Ovid(1980年至2018年1月23日)。检索了美国国立卫生研究院正在进行的试验注册库ClinicalTrials.gov和世界卫生组织国际临床试验注册平台,以查找正在进行的试验(2018年1月23日)。在检索电子数据库时,我们对语言或出版日期没有限制。
在所有年龄组中,比较缓释氟化物装置与其他氟化物治疗、安慰剂或不干预的平行随机对照试验(RCT)。主要寻求的结局指标是龋失补牙或面的数量(恒牙为DMFT/DMFS,乳牙为dmft/dmfs)的变化,以及龋损从釉质进展到牙本质的情况。
我们使用标准的Cochrane系统评价方法进行数据收集和分析。至少两名系统评价作者独立完成系统评价中的所有关键步骤,如摘要筛选、纳入标准应用、数据提取和偏倚风险评估。我们通过讨论或由第三位或第四位系统评价作者进行仲裁来解决分歧。
我们没有找到将缓释氟化物装置与其他类型氟化物疗法进行比较的证据。我们仅发现一项涉及174名儿童的双盲RCT,该试验比较了一种缓释氟化物装置(将含氟玻璃珠附着于右上颌第一恒磨牙的颊面)与对照组(将不含氟的玻璃珠附着于右上颌第一恒磨牙的颊面)。该研究被评估为存在高偏倚风险。该研究从一个贫困地区的七所学校招募儿童,该地区水中氟含量较低。研究开始时的平均年龄为8.8岁,结束时为10.9岁。在研究开始时,恒牙的DMFT或乳牙的dmft大于1,且每毫升唾液中变形链球菌的菌落形成单位大于100万。尽管在两年结束时仍有132名儿童纳入试验,但仅对保留了珠子的63名儿童(干预组31名,对照组32名)进行了检查和统计分析(两年时的保留率为47.7%)。在这63名儿童中,据报道干预组的龋病增量在统计学上显著低于对照组(DMFT:平均差值-0.72,95%置信区间(CI)-1.23至-0.21;DMFS:平均差值-1.52,95%CI-2.68至-0.36(极低质量证据))。尽管这种差异具有临床意义,但仅适用于那些保留氟化物珠子的儿童;超过50%的儿童没有保留珠子。试验报告中未报告不良事件。本系统评价中寻求的其他结局(龋损进展、牙痛、医疗保健利用数据)的证据也未报告。
没有足够的证据来确定缓释氟化物玻璃珠的防龋效果。现有证据质量极低,对普通儿童的益处可能被高估。这些研究结果对更广泛人群的适用性尚不清楚;该研究纳入了来自饮用水中氟含量低的贫困地区的儿童,这些儿童被认为患龋风险高。此外,证据仅来自两年时仍附着有珠子的儿童(占所有可用儿童中的48%);较早丢失缓释氟化物装置的儿童可能没有从这些装置中获得同样多的益处。